IASO Bio
PrivateLast Round
Series C
Extension
Sep 1, 2025
Total Funding Raised
$303.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
IASO Bio is a biopharmaceutical company that develops innovative cell therapies and biologics for the treatment of hematological malignancies and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IASO Bio Comparables
Compare IASO Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CARsgen Therapeutics | 87% | |
| Wuhan Bio-Raid Biotechnology | 85% | |
| Innovent Biologics | 84% |
IASO Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 1, 2025 | ||||
| Strategic | Jul 5, 2024 | ||||
| Series C Extension | Jan 17, 2023 | ||||
| Series C | Sep 16, 2021 | ||||
| Series B | Mar 24, 2020 | ||||
Series A | Oct 1, 2019 |
IASO Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hongcheng Capital | Series C Extension |
| CDH Investments | Series C |
| CNCB Investment | Series C |
| CDH Baifu | Series C |
| Hillhouse Investment | Series B, Series A |
| Housen Care Brothers | Series C Extension |
| CCB International | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
Partnered with Instituto Butantan to expand access in Brazil.
- Oct 29, 2025
Partnered with GC Cell to enter the Korean market.
Recent news
Latest coverage and updates
- attends_eventSep 27, 2026
IASO Bio attended event IMS Annual Meeting on Jul 1st '26.
- is_developingSep 16, 2026
IASO Bio is developing IASO208 on Sep 16th '26.
- acquiresAug 13, 2026
IASO Bio acquired MediSix on Aug 13th '26.
- partners_withAug 13, 2026
IASO Bio partners with Innovent.
- partners_withAug 13, 2026
IASO Bio partnered with Umoja Biopharma on Nov 1st '22.
IASO Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about IASO Bio's valuation, stock price, and market status.
Is IASO BIO a public or private company?
IASO BIO is a private company.
What is the current stock price of IASO BIO?
IASO BIO is a private company with no public stock price. No recent secondary market data is available.
How much is IASO BIO worth (valuation)?
Valuation information for IASO BIO is not publicly available.
Can I buy IASO BIO stock?
IASO BIO shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was IASO BIO's last funding round?
IASO BIO's most recent funding round was Series C Extension on September 1, 2025.
Who are the main investors in IASO BIO?
Key investors in IASO BIO include CDH Investments, CNCB Investment, Hillhouse Investment, Housen Care Brothers, CCB International.
Will IASO BIO IPO soon?
No public IPO plans have been announced for IASO BIO.
How can I track IASO BIO secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor IASO BIO's secondary market activity and sign up for updates.